Published: February 2023
Rise in clinical research activity for genetically modified therapies has resulted in the increase in demand for vectors; offering lucrative opportunities to players having capabilities for in-house and contract manufacturing of various types of vectors
Roots Analysis has announced the addition of “Viral Vector, Non-Viral Vector and Gene Therapy Manufacturing Market (5th Edition), 2022-2035” report to its list of offerings.
Over the past few years, cell and gene therapies have gained significant popularity owing to their therapeutic potential. In fact, more than 20 genetically modified therapies have already been approved, which has resulted in the increase in demand for vectors, which have proven to be highly efficient for the delivery of genetic material to the targeted area. In order to cater to the growing demand, several companies are offering diverse range of services for vector and gene therapy manufacturing.
To order this 685+ pages report, which features 200+ figures and 285+ tables, please visit this link
More than 140 stakeholders claim to manufacture viral and non-viral vectors
The market is currently dominated by the presence of various mid-sized industry players (50%); of these 57% of players are contract manufacturers, whereas 22% of players are in-house manufacturers.
Over the time, several advancements have been made for the development of vector based technological platforms
Majority (37%) of the available technologies are currently used in vector manufacturing followed by those available for manufacturing of cell and gene therapies (16%). Further, 53% of the vector-based technologies are dedicated for the development and manufacturing of adenoviral vectors.
More than 295 partnerships were established between different stakeholders during the last decade
Close to 55% partnerships have been reported post 2018, wherein, maximum partnerships were recorded in year 2022 (till May). Further, maximum partnerships were related to manufacturing (23%) followed by licensing agreement (20%) and product development agreement (15%).
Close to 120 expansion activities have been recorded till 2022, growing at a CAGR of 10%
Majority of the expansions in this domain were related to the establishment of new facility (39%) followed by facility expansion (12%).
The installed vector manufacturing capacity is estimated to be ~186,150 L
Majority (70%) of total installed capacity is currently available for clinical / commercial stage manufacturing of viral vectors. Further, players headquartered in North America (56%) have the highest installed capacity, across the globe.
Till 2035, the annual demand for vectors is expected to grow at an annualized rate of 11%
Currently, North America and Europe contribute to more than 70% of the demand for viral and non-viral vectors. By 2035, the demand, in terms of number of patients in clinical and commercial stage, demand for vectors, is projected to be ~ 400 thousand patients.
The market is anticipated to grow at a significant rate, during the period 2022-2035
The majority share of service revenues is anticipated to come from vector manufacturing projects focused on oncological disorders (51%). By 2035, Europe is likely to capture the major share (42%) of the market followed by North America (30%) and Asia-Pacific (23%).
To request a sample copy / brochure of this report, please visit this link
By 2035, the financial opportunity within the viral vector, non-viral vector and gene therapy manufacturing market has been analyzed across the following segments:
The report also features inputs from eminent industry stakeholders, according to whom, the anticipated increase in demand for cell and gene therapies, is the most prominent driver of the growth of the vector supply market. The report includes detailed transcripts of discussion held with prominent industry representatives:
The research includes profiles of key players (listed below), featuring a brief overview of the company, its financial performance (if available), information related to its manufacturing facilities, proprietary vector manufacturing technology and an informed future outlook.:
For additional details, please visit https://www.rootsanalysis.com/reports/view_document/viral-vectors-non-viral-vectors-and-gene-therapy-manufacturing-market-/274.html or email email@example.com
You may also be interested in the following titles:
+1 (415) 800 3415
+44 (122) 391 1091
We are your partners with no equity
We fit in your budget
We love what we do
Chance to prove ourselves
Best in class quality of work
Most trusted consulting partner in the industry
SUBSCRIBE TO INDUSTRY UPDATES